Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:S1–S276. doi: 10.1016/j.kint.2021.05.021
Lafayette R, et al.; NefIgArd Trial Investigators. Efficacy and Safety of a Targeted-Release Formulation of Budesonide in Patients with Primary IgA Nephropathy (NefIgArd): 2-Year results from a randomised phase 3 trial. Lancet 2023; 402:859–870. doi: 10.1016/S0140-6736(23)01554-4. Erratum: Lancet 2023; 402: 850. doi: 10.1016/S0140-6736(23)01851-2
Medjeral-Thomas NR, et al. Complement activation in IgA nephropathy. Semin Immunopathol 2021; 43:679–690. doi: 10.1007/s00281-021-00882-9
Caravaca-Fontán F, et al. Targeting complement in IgA nephropathy. Clin Kidney J 2023; 16(Suppl 2):ii28–ii39. doi: 10.1093/ckj/sfad198
Barratt J, et al.; Cemdisiran Phase 2 Study Investigators and Collaborators. Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: A randomized controlled trial. Clin J Am Soc Nephrol (published online January 15, 2024). doi: 10.2215/CJN.0000000000000384
Wheeler DC, et al.; DAPA-CKD Trial Committees and Investigators. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021; 100:215–224. doi: 10.1016/j.kint.2021.03.033